{"classes":[{"categories":[{"measurements":[{"groupId":"OG004","lowerLimit":"5.5","upperLimit":"15.2","value":"10.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"3"}],"units":"Participants"}],"description":"DOR: Time from first documentation of OR(sCR,CR,VGPR/PR) to first documentation of PD/death due to any cause, whichever came first. PD: Objective evidence of tumor progression(TP) (based on serum, urine/BM assessments) \\&/clinical progression/ investigator. sCR: CR, normal FLC ratio \\& absence of clonal cells in bone marrow by IC/IF. CR: Negative immunofixation of serum\\&urine, disappearance of any STP, \\&\\<5% plasma cells in bone marrow. VGPR: Serum \\& UMP detectable by immunofixation but not on electrophoresis/ \\>= 90% reduction(R) in SMP level+UMP level \\<100 mg/24 hour, PR: \\>=50%R of SMP \\& R in 24-hour UMP by \\>=90% or to \\<200 mg/24 hour. DOR: censored on date of last disease assessment documenting absence of PD for participants who do not have PD \\& were still on study at the time of an analysis/removed from study prior to documentation of TP. Participants started new antitumor treatment prior to documentation of PD were censored at last disease assessment prior to start of new treatment.","dispersionType":"Full Range","groups":[{"description":"Participants received SEA-BCMA 100 mg as a monotherapy q2wk IV on Day 1 and 15 of each 28- day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurs first.","id":"OG000","title":"Part A: SEA-BCMA 100mg"},{"description":"Participants received SEA-BCMA 200 mg as a monotherapy q2wk IV on Day 1 and 15 of each 28- day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurs first.","id":"OG001","title":"Part A: SEA-BCMA 200mg"},{"description":"Participants received SEA-BCMA 400 mg as a monotherapy q2wk IV on Day 1 and 15 of each 28- day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurs first.","id":"OG002","title":"Part A: SEA-BCMA 400mg"},{"description":"Participants received SEA-BCMA 800 mg as a monotherapy q2wk IV on Day 1 and 15 of each 28- day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurs first.","id":"OG003","title":"Part A: SEA-BCMA 800mg"},{"description":"Participants received SEA-BCMA 1600 mg as a monotherapy q2wk IV on Day 1 and 15 of each 28- day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurs first.","id":"OG004","title":"Part A: SEA-BCMA 1600mg"}],"paramType":"MEDIAN","populationDescription":"All treated participants analysis set included all treated participants who received any amount of SEA-BCMA. Here \"Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From the first dose of study treatment until the first documented OR (sCR or CR or PR or VGPR) on or before the first documented PD or death or censoring date, whichever occurred first (maximum up to 45 months)","title":"Duration of Objective Response (DOR) as Per the IMWG Uniform Response Criteria: Part A","type":"SECONDARY","unitOfMeasure":"Months"}